@misc{oai:repo.qst.go.jp:00077294,
 author = {李, 惠子 and 長谷川, 純崇 and Li, Huizi and Hasegawa, Sumitaka},
 month = {Nov},
 note = {Gastric cancer (GC) patients often already have distant metastasis at the time of diagnosis, and 4-14% of them are liver metastasis (LMGC) with dismal prognosis. Trastuzumab, a humanized anti-HER2 monoclonal antibody, is clinically used for the treatment of HER2-positive (HER2+) GC, which account for about 20% of GC. 
Alpha-radioimmunotherapy (α-RIT) is getting higher attention as a novel therapeutic option for metastasis, benefited from the combination of advantages of antibodies, cancer specific targeting, and alpha particles, high cell killing effects and short range. Astatine 211 (211At) is one of the attractiveα-emitter for clinical use. 
In this study, we investigated the therapeutic efficacy and toxicity using preclinical HER2+ LMGC mice model and provided the proof of concept thatα-RIT with 211At-trastuzumab has high potential as a novel therapeutic option against HER2+ LMGC., 第59回日本核医学会学術総会},
 title = {HER2高発現胃がん肝転移に対する新規アルファ線放射免疫療法},
 year = {2019}
}